Abstract: Solid-fuel rocket propellants comprising an oxidizer, an oxophilic metal-halophilic metal formulation, and a binder are described herein. Further described are processes for preparing such propellants and methods of reducing hydrogen chloride production via the combustion of such propellants. Non-limiting examples of such formulations include aluminum-lithium alloys.

Abstract: The present invention relates to a catalyst comprising a phosphorus modified zeolite, said phosphorus modified zeolite having partly an ALPO structure, wherein, the catalyst comprises a P-modified zeolite and a binder, the zeolite comprises at least one ten members ring in the structure, optionally the catalyst comprises one or more metal oxides, the ALPO structure is determined by a signal between 35-45 ppm in 27Al MAS NMR spectrum. The present invention also relates to the use of the above catalyst wherein said catalyst is operated in presence of steam at high temperature. “high temperature” means above 300° C. and up to 800° C. By way of example one can cite, the alcohol dehydration to convert at least an alcohol into the corresponding olefin, the olefin cracking to make lighter olefins, the MTO and the alkylation of aromatic compounds with olefins and/or alcohols to produce, by way of example, para-xylene, ethylbenzene, cumene etc.

Abstract: Processes and systems for the integrated production of propylene and an alkylate, such as cumene, may include feeding a hydrocarbon feedstock containing propane to a propane dehydrogenation reaction zone to convert a portion of the propane to propylene. The propylene is separated in a separation system to form a polymer-grade propylene stream, a low purity propylene stream, and a propane stream. The low purity propylene stream is then fed to an alkylation reaction zone where the propylene is reacted to produce an alkylated product and generate a low pressure steam. The low pressure steam may then be fed to the separation system as a heat source, integrating the dehydrogenation system and the alkylation system.

Abstract: An integrated process, suitable for use in a new or retrofitted plant, produces an olefin or di-olefin via the dehydrogenation of an appropriate C3-C4 hydrocarbon feed includes (1) contacting the feed and a dehydrogenation catalyst having a Geldart A or Geldart B classification in a fluidized bed at a temperature from 550° C. to 760° C. and a pressure from about 41.4 to about 308.2 kPa (about 6.0 to about 44.7 psia) and a catalyst to feed ratio, w/w, from 5 to 100 to form a dehydrogenate product; separating the dehydrogenate product and unreacted starting feed mixture from a portion of the catalyst by means of a cyclonic separation system; reactivating the catalyst in a fluidized regenerator by combustion at 660° C. to 850° C., followed by contact with an oxygen-containing fluid at 660° C.

Abstract: Apparatuses and processes are provided for regulating C7 and C8 feed to an aromatics complex to increase the ratio of a selected xylene isomer to benzene ratio. Reformate may be split into three cuts in a splitter column. A side cut stream comprises predominantly C7 hydrocarbons and a bottoms steam from the splitter column comprises predominantly C8+ hydrocarbons. The relative proportion of the C7 and C8+ hydrocarbon streams sent to the aromatics complex are metered to determine the resulting ratio of a selected xylene isomer to benzene produced by the aromatics complex.

Abstract: The invention provides a process for the separation of MEG and 1,2-BDO from a first mixture comprising MEG and 1,2-BDO in a weight ratio of at least 10:1 (MEG:1,2- BDO), said process comprising the steps of; (i) providing the first mixture as a feed to a distillation column at a point in the range of from 20 to 80% of the column height; (ii) operating the distillation at a temperature in the range of from 120 to 190° C. and at a pressure in the range of from 5 kPa to atmospheric pressure; (iii) removing an MEG stream from the distillation column at a point below the point at which the first mixture is fed; (iv) removing an overheads stream comprising an azeotrope of MEG and 1,2-BDO.

Abstract: A method for cultivating Monarda fistulosa for production of thymoquinone includes planting seeds at rates between about 2.5 and about 5 pounds per acre, preferably about 4 pounds per acre. The heavy rate of planting produces plants bearing oil without weed contamination and reduces herbicide use due to production of natural herbicides by the monarda plants. Seeding and mowing the first season, and harvesting in seasons thereafter reduce costs. The method results in increased production of essential oils including thymoquinone and thymohydroquinone at levels up to about 40% or more of recovered oils, and which may be distilled from the plant.

Abstract: New methods of preparing bridged bi-aromatic ligands are disclosed. The methods employ direct di-ortho-lithiation of aromatic rings of bridged protected bi-aromatic diphenols. The ligands may be used to prepare transition metal compounds useful as catalysts in olefin polymerization.

Abstract: A method of purifying a stream having an aromatic carboxy-aldehyde and an aromatic acid or the corresponding anhydride is described. The method includes reacting a hydroxylamine-containing compound with the aromatic carboxy-aldehyde in the stream to form a reaction mixture including the corresponding nitrone; adding an aqueous solvent to the reaction mixture, in an amount and under conditions effective to solubilize the nitrone but not the organic acid or the corresponding anhydride; and separating the solubilized nitrone from the non-solubilized organic acid. The nitrone is a water soluble nitrone.

Abstract: The invention is directed to a process for recovering/purifying (meth)acrylic acid which does not use azeotropic solvent and is based on the use of two columns for purifying a reaction mixture comprising (meth)acrylic acid. The process according to the invention includes a dry vacuum pump condensation system, which makes it possible to reduce the amount of final aqueous discharges.

Abstract: The invention relates to new compounds of the general formula (I): as well as the use thereof in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, in particular), or in the use of cosmetic compositions.

Abstract: The invention provides a method for producing halogenated carbonates, the method comprising reacting a halogenated alcohol or diol with a solid source of carbonyl moiety as a base in an ether.

Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

Abstract: An amine of formula (I) which is particularly suitable for use as a curing agent for epoxy resins. The amine of formula (I) is devoid of non-incorporable toxic phenols, and is low-viscosity and pale in colour. It allows the production of easily-workable, low-emission or emission-free epoxy resin products which cure rapidly even at relatively low ambient temperatures thus obtaining a high degree of hardness and a nice surface with hardly any yellowing. This is particularly suited to use in floor or top coatings.

Abstract: Provided is a glaucocalyxin A derivative, or salt thereof, as represented by the formula (I), a method for preparation of said glaucocalyxin A derivative, and a use for said glaucocalyxin A derivative in preparing pharmaceuticals for fighting autoimmune diseases and tumors, e.g.

Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

Abstract: The invention relates to a thermal conversion vessel (200) used during amidification step of acetone cyanohydrin (ACH), in the industrial process for production of a methyl methacrylate (MMA) or methacrylic acid (MAA). The thermal conversion vessel (200) is used for converting an hydrolysis mixture of ?-hydroxyisobutyramide (HIBAM), ?-sulfatoisobutyramide (SIBAM), 2-methacrylamide (MACRYDE) and methacrylique acid (MAA), into a mixture of 2-methacrylamide (MACRYDE). It comprises: at least one compartment (C1, C2, C3, . . . Ci) comprising an inner wall (206a, 206b, 206i) separating said compartment into two communicating parts (C1a, C1b) by a passage provided between the bottom of said vessel and said inner wall, said compartment having a space above said inner wall, for separating gas phase from liquid phase during thermal conversion, said compartment being connected to an outlet valve (204a, 204b, . . . 204i). Such vessel allows obtaining a high yield thermal conversion in very safe conditions.

Abstract: The present invention discloses an improved catalyst free process for synthesis of alkyl carbamates in an integrated system comprising a tubular reactor and a striper. The process comprises reacting urea and an alcohol in said tubular reactor under autogeneous pressure; wherein said process provides >90% selectivity towards alkyl carbamate. The mixture of urea and alcohol is N fed to the tubular reactor at a particular feed rate. The tubular reactor is heated externally under autogeneous pressure to carry out a synthesis reaction producing alkyl carbamate and ammonia. The ammonia is removed from the tubular reactor by the striper. The tubular reactor and the stripper are arranged in series to reduce the equilibrium limitations of the reaction and drive the reaction in forward direction.

Abstract: A method for producing an alkylamine derivative having a urea bond represented by formula (I), or a salt thereof, comprises the following steps (a) and (b), step (a): and step (b): deprotecting as necessary the reaction product obtained in step (a). The production method suitable for industrialization of the alkylamine derivative having a urea bond represented by formula (I), which is a compound highly useful as an agent having CaSR agonist effects is provided.

Abstract: There is disclosed a process for producing taurine from ammonium isethionate by the ammonolysis of alkali isethionate in the presence of alkali ditaurinate or alkali tritaurinate, or their mixture, to inhibit the formation of byproducts and to continuously convert the byproducts of the ammonolysis reaction to alkali taurinate. Alkali taurinate is reacted with ammonium isethionate to obtain taurine and to regenerate alkali isethionate. The production yield is increased to from 90% to nearly quantitative. The ammonolysis reaction is catalyzed by alkali salts of hydroxide, sulfate, sulfite, phosphate, or carbonate.

Abstract: The present invention relates to a new process for preparing 3-chloro-2-vinylphenylsulfonate derivatives.

Abstract: Compositions comprising branched C10 mercaptans selected from the group consisting of 5-methyl-1-mercapto-nonane, 3-propyl-1-mercapto-heptane, 4-ethyl-1-mercapto-octane, 2-butyl-1-mercapto-hexane, 5-methyl-2-mercapto-nonane, 3-propyl-2-mercapto-heptane, 4-ethyl-2-mercapto-octane, 5-methyl-5-mercapto-nonane, and combinations thereof. Compositions comprising C11+ mercaptans, wherein the C11+ mercaptans are characterized by structure R6—SH, wherein R6 is an alkyl group derived from one or more C11+ monoolefins, and wherein the one or more C11+ monoolefins comprise C11 internal monoolefins, C12 internal monoolefins, C13 internal monoolefins, C14 internal monoolefins, 1-tetradecene, 1-hexadecene, or combinations thereof. Compositions comprising branched C10+ mercaptans, wherein the branched C10+ mercaptans are characterized by structure R14—SH, wherein R14 is an alkyl group derived from one or more branched C10 to C30 monoolefins.

Abstract: According to the present invention, it is possible to provide a polythiol composition, which comprises a polythiol (A) represented by formula (1) and a thiol compound (B) represented by formula (2). (In formula (1), p and q each independently represent an integer of 1 to 3.) (In formula (2), p and q each independently represent an integer of 1 to 3.

Abstract: Compounds of formula (I): wherein R1 and R2 represent hydrogen or deuterium atoms; R3 represents a hydrogen atom or a —COOH, a —OH or a —OPO(OH)2 group; R4 represents a hydrogen atom or a fluorine atom; R5 represents a hydrogen atom or a —OH group; wherein at least one of R3 or R5 is different from a hydrogen atom; when R3 represents a —COOH, —OH or —OPO(OH)2 group, then R5 represents a hydrogen atom; when R5 represents a —OH group, then R3 and R4 represent hydrogen atoms; and R6 is selected from an optionally substituted phenyl, heteroaryl, cycloalkyl and heterocycloalkyl group; and the preparation and the therapeutic uses of the compounds of formula (I) as inhibitors and degraders of estrogen receptors, useful especially in the treatment of cancer.

Abstract: The present invention relates to redox electrolyte compounds. The present invention further relates to a redox-flow battery wherein one of the catholyte and the anolyte, or both, has the redox electrolyte compound of the invention. The present invention further relates to the method of controlling the redox-flow battery and its use for energy storage.

Abstract: A compound which is the hydrobromide salt of N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N?-(3-fluoro-2-methylphenyl)urea, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments.

Abstract: The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.

Abstract: Provide are: a sulfonic acid derivative compound which has high absorbance for light having a wavelength of 365 nm and exhibits high solubility in organic solvents and good acid generation rate; a photoacid generator; a resist composition; a cationic polymerization initiator; and a cationically polymerizable composition. The sulfonic acid derivative compound is represented by the following Formula (I): (wherein, X represents a linear or branched alkyl group having 1 to 14 carbon atoms; and R represents an aliphatic hydrocarbon group having 1 to 18 carbon atoms, an aryl group having 6 to 20 carbon atoms, an arylalkyl group having 7 to 20 carbon atoms, an acyl group-substituted aryl group having 7 to 20 carbon atoms, an alicyclic hydrocarbon group having 3 to 12 carbon atoms, a 10-camphoryl group or the like).

Abstract: The invention relates to a production method of pyrazole derivative (6) by reacting compound (5) with an oxidant. wherein R1, R2, R3, X1, X2 and Z1 are as defined herein.

Abstract: The invention provides compounds that are useful as sodium channel blockers. In one aspect, the invention provides compounds of Formula I: and pharmaceutically acceptable salts, solvates, hydrates, or diastereomers thereof, wherein W1, W2, W3, W4, U, G, m, R1, and R2 are defined in the disclosure. In certain embodiments, the invention provides compounds of Formulae II to V as set forth supra. The invention also provides the use of compounds of any of the above discussed formulae to treat a disorder responsive to blockade of sodium channels. In one embodiment, Compounds of the Invention are useful for treating pain.

Abstract: The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound. A compound of Formula: or its pharmaceutically acceptable salt, wherein, R1 is substituted or unsubstituted fused aromatic heterocyclyl represented by Formula: wherein, ring B is 5-membered ring, ring C is 6-membered ring; ring A is substituted or unsubstituted non-aromatic carbocycle or the like; -L1- is —O—(CR6R7)m- or the like; -L2- is —O—(CR6R7)n- or the like; each R6 is independently hydrogen or the like; each R7 is independently hydrogen or the like; each m is independently an integer of 0, 1, 2 or 3; each n is independently an integer of 1, 2 or 3; R2 is substituted or unsubstituted alkyl; R3 is hydrogen or substituted or unsubstituted alkyl; R4 is substituted or unsubstituted alkylcarbonyl or the like.

Abstract: Salts of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium, method of preparation thereof and use in the treatment of cardiovascular disease.

Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.

Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.

Abstract: Disclosed are two axially chiral isomers and pharmaceutically available salts thereof, preparation method therefor, and pharmaceutical use of the two axially chiral isomers or pharmaceutical compositions thereof.

Abstract: A novel asymmetric diamine, diamino-2-(benzothiazole-2-yl)diphenyl ether, derivatives therefor, and an intermediate for the compound such as aminonitro-2-(benzothiazole-2-yl)diphenyl ether, dinitro-2-(benzothiazole-2-yl)diphenyl ether, and derivatives from these. Additionally, another novel asymmetric diamine, diamino-2-(benzoxazole-2-yl)diphenyl ether, derivatives therefor, and intermediate for the compound such as aminonitro-2-(benzoxazole-2-yl)diphenyl ether, dinitro-2-(benzoxazole-2-yl)diphenyl ether, and derivatives from these, and methods for preparing them.

Abstract: Compositions and processes for producing high purity acesulfame potassium are described. One process comprises the steps of forming a cyclic sulfur trioxide adduct; hydrolyzing the cyclic sulfur trioxide adduct to form an acesulfame-H composition comprising acesulfame-H; neutralizing the acesulfame-H in the acesulfame-H composition to form a crude acesulfame potassium composition comprising acesulfame potassium and less than 2800 wppm acetoacetamide-N-sulfonic acid, wherein the neutralizing step is conducted or maintained at a pH at or below 11.0; and treating the crude acesulfame potassium composition to form the finished acesulfame potassium composition comprising acesulfame potassium and less than 37 wppm acetoacetamide-N-sulfonic acid.

Abstract: Compositions and processes for producing high purity acesulfame potassium are described. One process comprises the steps of providing a crude acesulfame potassium composition comprising acesulfame potassium and acetoacetamide, concentrating the crude acesulfame potassium composition to form a water stream and an intermediate acesulfame potassium composition comprising acesulfame potassium and less than 33 wppm acetoacetamide, and separating the intermediate acesulfame potassium composition to form the finished acesulfame potassium composition comprising acesulfame potassium and less than 33 wppm acetoacetamide. The concentrating step is conducted at a temperature below 90° C. and the separating step is conducted at a temperature at or below 35° C.

Abstract: A process for producing acesulfame potassium, the process comprising the steps of providing a cyclizing agent composition comprising a cyclizing agent and a solvent and having an initial temperature, cooling the cyclizing agent composition to form a cooled cyclizing agent composition having a cooled temperature less than 35° C., reacting an acetoacetamide salt with the cyclizing agent in the cooled cyclizing agent composition to form a cyclic sulfur trioxide adduct composition comprising cyclic sulfur trioxide adduct; and, forming from the cyclic sulfur trioxide adduct in the cyclic sulfur trioxide adduct composition the finished acesulfame potassium composition comprising non-chlorinated acesulfame potassium and less than 39 wppm 5-chloro-acesulfame potassium. The cooled temperature is at least 2° C. less than the initial temperature.

Abstract: Improved processes for producing high purity acesulfame potassium. In one embodiment, the process comprises the steps of contacting a solvent, e.g., dichloromethane, and a cyclizing agent, e.g., sulfur trioxide, to form a cyclizing agent composition and reacting an acetoacetamide salt with the cyclizing agent in the composition to form a cyclic sulfur trioxide adduct. The contact time is less than 60 minutes. The process also comprises forming from the cyclic sulfur trioxide adduct composition a finished acesulfame potassium composition comprising non-chlorinated, e.g., non-chlorinated, acesulfame potassium and less than 35 wppm 5-halo acesulfame potassium, preferably less than 5 wppm.

Abstract: Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

Abstract: Provided are: an aromatic sulfonium salt compound which exhibits low corrosion to a substrate and excellent photolithographic characteristics and is thus useful as a photoacid generator and as a cationic polymerization agent; and a photoacid generator, a resist composition, a cationic polymerization initiator and a cationically polymerizable agent composition, which include the aromatic sulfonium salt compound. The aromatic sulfonium salt compound is represented by the following Formula (I): (wherein, R1 to R10 each independently represent a hydrogen atom, a halogen atom, a hydroxyl group, a nitro group, a cyano group, an alkyl group having 1 to 18 carbon atoms which is optionally substituted, or the like; R11 to R15 each independently represent a hydrogen atom, an alkoxy group having 1 to 18 carbon atoms which is optionally substituted, or the like; at least one of R11 to R15 is not a hydrogen atom; and X1? represents a monovalent organic sulfonate anion).

Abstract: A method for manufacturing an insecticidal compound and insecticidal compositions comprising the insecticidal compound and methods of use are presented herein. The manufacturing method presented herein allows for a high purity grade of thiocyclam hydrochloride to be synthesized. The insecticidal compositions comprising the thiocyclam hydrochloride can be used for prevention of crop destruction by insects. The use of thiocyclam hydrochloride in insecticidal compositions as described herein can achieve greater efficacy than previously known insecticides, by eliminating the insect pests more reliably and efficiently.

Abstract: Compounds of the formula (I) wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and to the use of the compounds or compositions in agriculture or horticulture for combating, preventing or controlling infestation of plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, in particular fungi.

Abstract: The present invention provides a method of efficiently producing an optically active 6-(3-aminopiperidin-1-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine derivative. The optically active piperidine-3-carboxamide or a derivative thereof, which is obtained by subjecting 1,4,5,6-tetrahydropyridine-3-carboxamide or a derivative thereof to an asymmetric reduction in the presence of a catalyst, is used as an intermediate.

Abstract: Described are deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds of structural Formula (I), which are agonists of 5-hydroxytryptamine receptors. Also described are pharmaceutical compositions comprising the deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds, and methods of use thereof.

Abstract: The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Abstract: Methods of preparing Ledipasvir and derivatives thereof, and intermediate compounds used in the preparation of Ledipasvir are provided. Specifically, a method for preparing the compounds of formula 1 and a series of preparation methods of preparing Ledipasvir are provided. The methods described herein are simple and efficient, and have better application prospects.

Abstract: The invention disclosed herein is directed to compounds of Formula I [Formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers.

Abstract: Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders.